Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REGENERON PHARMACEUTICALS

(REGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Regeneron, Sanofi : Dupixent Hits Main Endpoints in Prurigo Nodularis Trial

10/22/2021 | 04:24am EST

By Colin Kellaher

Regeneron Pharmaceuticals Inc. and Sanofi SA on Friday said a Phase 3 study of their blockbuster eczema drug Dupixent in the chronic skin condition prurigo nodularis met its primary and all secondary endpoints.

The companies said Dupixent significantly reduced itch at 12 weeks, while nearly three times as many Dupixent patients experienced reductions in both itch and skin lesions at 24 weeks compared to placebo.

Regeneron and Sanofi said prurigo nodularis is the sixth disease where Dupixent has shown positive Phase 3 results, adding that they plan to begin regulatory submissions next year.

Regeneron, of Tarrytown, N.Y., created Dupixent and markets it jointly in the U.S. with France's Sanofi under a 2007 collaboration agreement. Sanofi markets the product internationally.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

10-22-21 0624ET

Stocks mentioned in the article
ChangeLast1st jan.
REGENERON PHARMACEUTICALS -0.75% 643.35 Delayed Quote.33.17%
SANOFI -1.89% 85.01 Real-time Quote.8.02%
All news about REGENERON PHARMACEUTICALS
11/26MarketScreener's World Press Review - November 26, 2021
11/26Merck's COVID-19 pill significantly less effective in new analysis
RE
11/23Nykode Therapeutics in Vaccine Deal With Regeneron Worth Up to $925 Million
DJ
11/23Nykode, Regeneron to Team Up On Cancer, Infectious Disease Vaccines
MT
11/23Nykode Therapeutics Enters into Collaboration Agreement with Regeneron to Develop Innov..
CI
11/23Vaccibody AS announced that it expects to receive NOK 178.305538 million in funding fro..
CI
11/22Regeneron Extends Research Collaboration With Decibel Therapeutics; Decibel Shares Rise..
MT
11/22Decibel Therapeutics, Inc. Announces Extension of Research Term Under Strategic Collabo..
CI
11/19BioNTech's Skin Cancer Vaccine Candidate Wins US FDA's Fast Track Status
MT
11/18WALL STREET STOCK EXCHANGE : Trading is the new online gambling
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS
More recommendations
Financials (USD)
Sales 2021 15 430 M - -
Net income 2021 7 903 M - -
Net cash 2021 5 814 M - -
P/E ratio 2021 9,19x
Yield 2021 -
Capitalization 67 266 M 67 266 M -
EV / Sales 2021 3,98x
EV / Sales 2022 4,46x
Nbr of Employees 9 766
Free-Float 81,9%
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 643,35 $
Average target price 697,52 $
Spread / Average Target 8,42%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl Executive VP-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
REGENERON PHARMACEUTICALS33.17%67 266
GILEAD SCIENCES, INC.20.61%88 146
BIONTECH SE326.89%84 049
WUXI APPTEC CO., LTD.24.40%64 416
VERTEX PHARMACEUTICALS-22.32%46 678
BEIGENE, LTD.34.56%32 622